location_continent,study_eligibility_criteria,study_eligibility_healthy_volunteers,study_eligibility_gender,study_eligibility_minimum_age,study_eligibility_maximum_age,study_eligibility_standard_age_list,study_eligibility_ethnicity,clinical_trial_study_name,clinical_trial_sponsor,clinical_trial_responsible_party,clinical_trial_study_type,clinical_trial_phase,clinical_trial_allocation,clinical_trial_intervention_model,clinical_trial_masking,clinical_trial_primary_purpose,clinical_trial_official_title,clinical_trial_actual_study_start_date,clinical_trial_actual_primary_completion_date,clinical_trial_actual_study_completion_date,outcome_overview_title,outcome_overview_id,outcome_overview_description,outcome_overview_time_frame,outcome_overview_assay,outcome_overview_dose_number,outcome_overview_participants,outcome_overview_serotype,outcome_overview_value,outcome_overview_upper_limit,outcome_overview_lower_limit,outcome_overview_vaccine,outcome_overview_immunocompromised_population,outcome_overview_manufacturer,outcome_overview_time_frame_weeks,outcome_overview_confidence_interval,outcome_overview_percent_responders
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,1,4.29,4.45,4.14,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,14,5.2,5.5,4.92,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,19A,1.64,1.72,1.57,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,6B,1.21,1.3,1.13,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,6A,1,1.06,0.95,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,9V,1.31,1.36,1.26,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,23F,1.58,1.66,1.51,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,7F,2.97,3.1,2.85,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,19F,4.35,4.54,4.17,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,IgG GMC after three doses of Pneumosil,4 weeks after the third dose,IgG,3,1458,5,1.65,1.71,1.59,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,5,1.2,1.26,1.14,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,1,1.99,2.11,1.88,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,19F,5.93,6.39,5.5,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,19A,1.13,1.25,1.02,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,7F,2.29,2.43,2.16,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,6B,1.13,1.25,1.02,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,6A,1.13,1.25,1.02,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,14,4.24,4.61,3.9,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,23F,0.87,0.95,0.8,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,IgG GMC after three doses of Synflorix,4 weeks after the third dose,IgG,3,724,9V,1.42,1.5,1.34,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,5,161.34,186.02,139.94,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,9V,141.72,177.16,113.36,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,19A,148.59,181.95,121.35,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,23F,767.24,907.1,648.95,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,7F,1833.71,2085.51,1612.31,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,19F,594.27,692.49,509.98,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,14,1019.34,1272.52,816.53,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,6B,913.52,1118.7,745.97,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,6A,1317.16,1563.88,1109.36,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three doses of Pneumosil,4 weeks after the third dose,OPA,3,247,1,85.17,101.69,71.34,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,9V,376.77,438.13,324.01,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,19A,11.09,13.39,9.19,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,1,27.55,33.06,22.96,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,23F,253.09,325,197.1,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,7F,1586.75,1807.94,1392.62,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,19F,895.39,1021.35,784.96,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,6A,7.06,8.56,5.83,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,5,115.93,135.97,98.85,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,14,1102.64,1383.87,878.56,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three doses of Synflorix,4 weeks after the third dose,OPA,3,250,6B,467.65,598.73,365.27,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,5,41.4,62,27.6,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,19F,133.5,261.1,68.2,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,1,11,15.1,8,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,6B,116.3,180.6,74.9,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,9V,114.5,205.5,63.8,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,19A,89.7,160.3,50.2,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,7F,1765.9,2518.8,1238.1,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,14,215.1,366.6,126.2,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,6A,118.1,226.5,61.6,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Pneumosil,OG000,Three primary doses + 1 booster dose of Pneumosil,One year post booster vaccination,OPA,4,50,23F,393.8,707.4,219.3,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,7F,1851.8,2740.5,1251.3,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,14,193.4,346.6,107.9,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,5,31.6,50.1,20,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,23F,91.6,155.3,54,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,19F,139.8,249.8,78.3,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,19A,17.6,28.3,11,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,9V,158.2,289.9,86.3,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,1,8.7,12.9,5.9,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,6A,8.3,13.6,5,PCV10 (Synflorix),,MSD,0,,0
Africa,"Inclusion Criteria:

They are healthy infants based on medical history and clinical assessment.
They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.
Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.

Exclusion Criteria:

Use of any investigational medicinal product prior to randomization.
Previous vaccination against or infection with S. pneumoniae.
History of anaphylactic shock or an allergic reaction to any prior vaccination.
Any fever, illness (including malaria).
Receipt of another vaccine within 30 days of study start.
Chronic administration of an immunosuppressant or administration of immunoglobulins
History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.
History of meningitis, seizures or any neurological disorder.",Accepts Healthy Volunteers,All,6 Weeks,8 Weeks,"[""Child""]","[""Race-African"",""Race-Other"",""Ethnicity-Mandinka"",""Ethnicity-Wolof"",""Ethnicity-Fula"",""Ethnicity-Jola"",""Ethnicity-Serahule"",""Ethnicity-Serere"",""Ethnicity-Manjago"",""Ethnicity-Other""]",Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants,PATH,PATH,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia",<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix,OG001,Three primary doses + 1 booster dose of Synflorix,One year post booster vaccination,OPA,4,50,6B,31.1,47.2,20.5,PCV10 (Synflorix),,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,22F,0.34,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,18C,9.58,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,5,4.66,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,6A,7.2,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,14,9.97,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,9V,4.97,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,19A,16.66,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,6B,7.28,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,7F,7.12,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,4,2.38,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,1,5.22,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,19F,10.25,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,23F,6.03,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG001,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,231,3,0.55,,,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,3,0.77,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,7F,6.19,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,1,3.91,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,22F,4.1,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,9V,4.3,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,14,9.89,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,19F,10.52,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,4,1.87,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,19A,16.18,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,18C,12.08,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,5,4.14,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,6B,10.92,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,23F,7.58,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,"V114 Combined Lots 1,2 and 3",OG000,"Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)",Day 30,IgG,0,2102,6A,8.38,,,PCV15,,MSD,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,3,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,22F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,7F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,19A,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,19F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,14,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,4,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,5,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,9V,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,23F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,18C,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,6B,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,1,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,IgG,0,0,6A,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,18C,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,9V,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,6A,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,22F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,5,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,7F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,19A,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,4,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,14,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,1,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,6B,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,23F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,19F,0,0,0,PCV13,,Pfizer,0,,0
"Europe,North America,North America,North America,North America,South America,Europe,North America,North America,Europe,North America,South America,South America,North America,Europe,North America,Europe,North America,North America,Europe,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,Europe,Australia & Oceania,Australia & Oceania,North America,North America,Europe,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,Europe,South America,Europe,North America,North America,North America,Europe,North America,Europe,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a time when criterion is not met.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar13™,OG003,Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1),Day 30,OPA,0,0,3,0,0,0,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,598,3,135.1,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,598,3,216.2,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,1,7.34,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,3,0.64,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,4,2.62,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,5,5.56,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,6A,7.01,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,6B,6.19,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,7F,8.09,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,9V,5.52,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,14,12.3,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,18C,10,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,19A,17.38,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,19F,9.7,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,23F,6.13,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,IgG,0,600,22F,0.32,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,1,5.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,3,0.96,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,4,1.88,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,5,4.57,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,6A,7.21,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,6B,8.6,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,7F,6.18,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,9V,4.77,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,14,9.39,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,18C,8.99,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,19A,14.6,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,19F,8.77,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,23F,6.67,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,IgG,0,602,22F,3.44,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,1,322.6,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,3,135.1,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,4,1661.6,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,5,563.5,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,6A,5424.5,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,6B,3258.2,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,7F,5880.6,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,9V,2232.9,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,14,2656.7,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,18C,2583.7,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,19A,3979.8,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,19F,1917.8,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,23F,1740.4,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1.,Day 30,OPA,0,600,22F,74.6,,,PCV13,,Pfizer,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,1,256.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,3,216.2,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,4,1125.6,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,5,447.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,6A,5407.2,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,6B,4011.7,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,7F,4617.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,9V,1817.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,14,1999.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,18C,2757.7,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,19A,3194.3,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,19F,1695.1,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,23F,2045.4,,,PCV15,,MSD,0,,0
"Asia,Europe,Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,Europe,Asia,Europe,North America,North America,North America,North America,North America,Asia,Asia,Asia,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Participant has good health in the opinion of the investigator. Any underlying chronic condition must be documented to be in stable condition according to the investigator's judgment.
Male or female ≥50 years of age at the time of signing the informed consent. (For Japan only: Is male or female ≥65 years of age at the time of signing the informed consent)
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participant is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use agreed upon contraception during the treatment period and for at least 6 weeks after the last dose of study intervention.
Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Exclusion Criteria:

History of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
Coagulation disorder contraindicating intramuscular (IM) vaccinations.
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1).
Has received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted.)
Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
Has received any non-live vaccine within the 14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine within 30 days following receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine.)
Has received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine.
Has received a blood transfusion or blood products, including immunoglobulin, within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.
Currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
An immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.,Day 30,OPA,0,602,22F,2375.2,,,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,1,50.8,62,41.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,3,31.1,36.1,26.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,4,149.9,190.1,118.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,5,62.8,74.9,52.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,6A,748.7,972,576.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,6B,727.3,922.1,573.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,7F,378.1,451.9,316.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,9V,550.3,666.9,454,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,14,391.2,486.3,314.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,18C,551.9,684.4,445.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,19A,238.6,288.4,197.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,19F,159,192.3,131.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,23F,151.6,199.3,115.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort A: 20vPnC,OG000,"Participants with receipt of 23-valent pneumococcal polysaccharide vaccine (PPSV23) greater than or equal to (>=) 1 to less than or equal to (<=) 5 years, and no 13-valent pneumococcal conjugate vaccine (13vPnC), prior to study vaccination, and randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) on Day 1.",1 month after vaccination,OPA,0,247,8,211.9,261,172,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,1,115.3,137.9,96.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,3,54.3,62.8,46.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,4,334.9,409.5,273.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,5,87.3,104.2,73.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,6A,1080.9,1327.4,880.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,6B,1159.4,1413.8,950.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,7F,555.4,660.9,466.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,9V,1085,1317.5,893.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,14,664.9,797.9,554.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,18C,845.9,1033.1,692.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,19A,365.1,440,303,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,19F,242.3,294.3,199.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,23F,450.2,566.4,357.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort B: 20vPnC,OG001,"Participants with receipt of 13vPnC, >=6 months, and no PPSV23, prior to study vaccination, and randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,243,8,602.9,752.8,482.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,1,82.1,110.1,61.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,3,39.3,48.2,32,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,4,193.7,262,143.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,5,83.5,107.6,64.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,6A,1085.3,1478.1,796.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,6B,1033.3,1414.8,754.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,7F,345.8,431.7,277,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,9V,723.4,937.6,558.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,14,580.5,777,433.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,18C,621.2,821.3,469.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,19A,340.6,439.2,264.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,19F,217.7,281.8,168.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,23F,292.6,420.5,203.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America","Inclusion Criteria

Male or female adults 65 years of age or greater.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

Male or female adults who meet 1 of the following:

Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort C: 20vPnC,OG002,"Participants with receipt of 13vPnC followed by PPSV23 (PPSV23 dose >=1 year) prior to study vaccination, received a single dose of 0.5 mL intramuscular injection of 20vPnC on Day 1.",1 month after vaccination,OPA,0,121,8,293.8,392.4,220,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,1,199.5,229.6,173.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,3,47.3,52.4,42.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,4,1499.7,1745.6,1288.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,5,125.8,145.7,108.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,6A,4654.1,5371,4033,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,6B,4403.3,5059,3832.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,7F,1820.6,2086.5,1588.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,9V,5120.4,5872.7,4464.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,14,2240.2,2553.5,1965.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,18C,3903.7,4563.2,3339.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,19A,1457.8,1650.6,1287.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,19F,524.5,610.3,450.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,23F,1416.1,1696.1,1182.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 1,OG000,Participants were randomized to receive a single 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) from Lot 1 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,463,8,1595,1813.7,1402.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,1,175.1,201,152.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,3,46.8,51.8,42.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,4,1568.2,1821.4,1350.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,5,135.6,156.7,117.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,6A,3748.3,4315.4,3255.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,6B,4349.9,4984.1,3796.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,7F,1865.6,2135.7,1629.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,9V,4604.1,5267.5,4024.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,14,2091.2,2376.8,1839.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,18C,4450.7,5188,3818.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,19A,1528.1,1725.6,1353.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,19F,529.2,614.6,455.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,23F,1547.5,1849.2,1294.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 2,OG001,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 2 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,473,8,1345.9,1527.6,1185.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,1,164.6,189.3,143.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,3,43.1,47.8,38.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,4,1505.6,1751.3,1294.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,5,116.8,135.2,100.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,6A,3330.4,3844.6,2885.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,6B,3907.3,4488.3,3401.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,7F,1875.7,2154.9,1632.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,9V,4921.7,5643.2,4292.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,14,2001.9,2276.5,1760.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,18C,4221.7,4929.2,3615.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,19A,1434.4,1623,1267.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,19F,549,638.3,472.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,23F,1434.6,1718.1,1197.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults ≥18 and <50 years of age.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
History of microbiologically proven invasive disease caused by S pneumoniae.
Pregnant female subjects or breastfeeding female subjects (known or suspected).",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Lot 3,OG002,Participants were randomized to receive a single 0.5 mL intramuscular injection of 20vPnC from Lot 3 on Day 1. Participants were followed up to 6 months after vaccination.,1 month after vaccination,OPA,0,456,8,1624.3,1844.5,1430.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,1,131.8,148.3,117.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,3,40.9,44.5,37.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,4,577.9,660.6,505.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,5,96.5,108.6,85.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,6A,997.1,1147.5,866.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,6B,1199,1363.4,1054.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,7F,1173,1306.9,1052.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,9V,1687.9,1907.3,1493.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,14,742.3,840.2,655.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,18C,1355.2,1550.7,1184.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,19A,600.3,670.6,537.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,19F,290.4,329,256.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,23F,327.5,385.6,278.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 1: 20vPnC/Saline (60-64 Years of Age),OG001,Participants were randomized to receive a single dose of 0.5 milliliter (mL) intramuscular injection of 20-valent pneumococcal vaccine (20vPnC) at Vaccination 1 (Day 1) and a single dose of 0.5 mL intramuscular injection of saline at Vaccination 2 (28 to 42 days after Vaccination 1).,1 month after vaccination,OPA,0,946,8,502.3,569.8,442.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,1,135.9,163.4,113.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,3,43.3,49.4,38,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,4,633.3,780.4,513.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,5,84.6,101.8,70.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,6A,1203.9,1497.1,968.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,6B,1502.7,1838.5,1228.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,7F,1047,1240.2,884,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,9V,1725.7,2090.6,1424.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,14,926.2,1126,761.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,18C,1805,2232.2,1459.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,19A,618.4,735.5,519.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,19F,286.7,348.2,236,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,23F,549.1,708.9,425.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 2: 20vPnC,OG000,Participants aged 50 through 59 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,321,8,486.9,591.9,400.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,1,162.6,195.6,135.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,3,42.1,48.1,36.9,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,4,1966.7,2418.3,1599.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,5,107.9,130.1,89.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,6A,3930.5,4864.4,3176,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,6B,4260,5243.1,3461.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,7F,1872.8,2242.4,1564.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,9V,6041.4,7354.9,4962.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,14,1848.4,2255.7,1514.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,18C,4460.5,5550.4,3584.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,19A,1415,1694.2,1181.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,19F,654.8,796.8,538.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,23F,1559.2,2012.2,1208.1,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
Pregnant female subjects or breastfeeding female subjects.",Accepts Healthy Volunteers,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",<time.Time Value>,<time.Time Value>,<time.Time Value>,Cohort 3: 20vPnC,OG000,Participants aged 18 through 49 years were randomized to receive a single dose of 0.5 mL intramuscular injection of 20vPnC (Day 1).,1 month after vaccination,OPA,0,317,8,867,1059.2,709.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,1,3.42,3.87,3.02,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,3,0.68,0.76,0.61,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,4,1.77,2.02,1.55,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,5,3.92,4.56,3.37,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,6A,4.88,5.85,4.08,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,6B,6.04,7.19,5.08,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,7F,4.07,4.68,3.54,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,9V,3.61,4.12,3.17,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,14,14.59,16.85,12.64,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,18C,4.24,4.84,3.71,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,19A,12.04,13.72,10.57,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,19F,8.81,10.02,7.74,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,23F,4.96,5.81,4.25,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,379,22F,4.76,5.65,4.01,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,1,2.91,3.12,2.71,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,3,0.66,0.71,0.62,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,4,1.33,1.44,1.23,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,5,3.45,3.75,3.17,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,6A,4.25,4.69,3.84,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,6B,6.79,7.49,6.15,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,7F,3.46,3.94,3.36,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,9V,3.18,3.43,2.96,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,14,14.28,15.53,13.13,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,18C,5.5,5.98,5.07,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,19A,11.26,12.11,10.47,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,19F,9.07,9.74,8.45,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,23F,5.42,5.89,4.98,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,IgG,0,1133,22F,4.85,5.23,4.5,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,1,4.59,5.26,4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,3,0.63,0.71,0.57,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,4,2.71,3.13,2.34,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,5,4.48,5.32,3.77,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,6A,10.87,13.05,9.06,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,6B,11.36,13.66,9.45,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,7F,6.88,7.95,5.95,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,9V,5.31,6.1,4.62,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,14,17.35,20.16,14.93,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,18C,9.32,10.79,8.06,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,19A,21.79,25.19,18.85,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,19F,13.35,15.47,11.52,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,23F,10.98,12.91,9.34,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,379,22F,0.52,0.6,0.45,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,1,3.56,3.85,3.29,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,3,0.77,0.83,0.72,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,4,1.53,1.66,1.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,5,3.43,3.75,3.14,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,6A,11.84,13.1,10.71,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,6B,17.9,19.76,16.21,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,7F,5.18,5.62,4.77,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,9V,4.44,4.8,4.11,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,14,15.91,17.51,14.46,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,18C,14.57,15.81,13.42,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,19A,19.41,20.93,18,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,19F,13.98,15.14,12.9,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,23F,13.57,14.8,12.44,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,IgG,0,1133,22F,6.22,6.74,5.74,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,1,214.4,254.5,180.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,3,208,240.7,179.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,4,1980.6,2214.6,1771.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,5,626.7,738.7,531.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,6A,5739.9,6623.1,4974.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,6B,4412.4,5001.5,3892.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,7F,6223.9,6923,5595.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,9V,3364.1,3807.6,2972.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,14,5317.6,6034.1,4686.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,18C,2294.4,2564.8,2052.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,19A,4286.4,4786.4,3838.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,19F,3085.4,3435.9,2770.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,23F,2896,3362.7,2494.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,379,22F,4060.2,4908.4,3358.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,1,266.6,291.8,243.6,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,3,211,228.1,195.2,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,4,1734.5,1856.4,1620.7,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,5,595.1,650.5,544.5,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,6A,5810.3,6290.3,5366.9,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,6B,5215.2,5592.2,4863.6,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,7F,6070.5,6465.6,5699.7,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,9V,3133.1,3363.7,2918.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,14,5644.9,6055.2,5262.5,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,18C,3260.6,3477.5,3057.3,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,19A,4336.2,4655.6,4038.6,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,19F,3198.6,3397.8,3011,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,23F,3057.3,3311,2823,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Month 7,OPA,0,1133,22F,3624,3880.3,3384.5,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,1,267.2,323.9,220.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,3,150.6,173.8,130.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,4,2576.1,2913.2,2278,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,5,731.1,871,613.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,6A,11282.4,13097.5,9718.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,6B,6995.7,8123.2,6024.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,7F,7588.9,8500.2,6775.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,9V,3983.7,4460.7,3557.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,14,5889.8,6647.8,5218.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,18C,3063.2,3475.5,2699.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,19A,5888,6631,5228.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,19F,3272.7,3632.9,2948.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,23F,3887.3,4530,3335.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,379,22F,291.6,383.6,221.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,1,268.6,296,243.7,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,3,199.3,215.2,184.6,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,4,1416,1531.8,1308.9,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,5,564.8,622.2,512.7,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,6A,12928.8,14019,11923.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,6B,10336.9,11073.4,9649.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,7F,5756.4,6124.6,5410.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,9V,3355.1,3590.1,3135.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,14,5228.9,5640.2,4847.6,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,18C,5709,6113.6,5331.1,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,19A,5369.9,5746.8,5017.7,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,19F,3266.3,3481.4,3064.4,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,23F,4853.5,5270.2,4469.8,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,South America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,South America,South America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America,Australia & Oceania,North America,Europe,North America,North America,Australia & Oceania,North America,North America,Australia & Oceania,Australia & Oceania,South America,Europe,North America,North America,North America,North America,North America,Europe Asia,Europe,North America,Europe,North America,Europe,North America,Australia & Oceania,Europe Asia,North America,Australia & Oceania,South America,North America,North America,Australia & Oceania,Europe,North America,North America,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,Australia & Oceania,North America,Australia & Oceania","Inclusion Criteria:

Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:

Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) <10%
Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)
Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3
Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy
Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.
Current smoker
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.

Exclusion Criteria:

History of active hepatitis within the prior 3 months
History of diabetic ketoacidosis, or >1 episodes of severe, symptomatic hypoglycemia within the prior 3 months
Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months
History of severe pulmonary hypertension or history of Eisenmenger syndrome
History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years
Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)
History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome
History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months
History of coagulation disorder contraindicating intramuscular vaccination
History of hospitalization within the prior 3 months
Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.
Expected survival for less than 1 year according to the investigator's judgment.
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days
Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination
Receiving immunosuppressive or immunomodulatory therapy with a biological agent
Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine
Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
Received a blood transfusion or blood products within the prior 6 months
Receiving chronic home oxygen therapy
Participated in another clinical study of an investigational product within the prior 2 months
Current user of recreational or illicit drugs or history of drug abuse or dependence
Diabetes mellitus with HgA1c ≥10%
Chronic liver disease with Child-Pugh Class B or C cirrhosis
Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma
Chronic heart disease with NYHA heart failure Class 4.",Accepts Healthy Volunteers,All,18 Years,49 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).,Day 30,OPA,0,1133,22F,3926.5,4228.7,3645.9,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,1,4.04,5,3.27,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,3,0.59,0.7,0.5,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,4,1.61,1.98,1.31,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,5,2.13,2.68,1.69,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,6A,3.71,5.03,2.74,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,6B,4.35,5.86,3.23,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,7F,3.17,3.87,2.6,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,9V,3.24,4.01,2.62,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,14,14.37,18.36,11.25,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,18C,3.96,4.95,3.18,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,19A,8.54,10.72,6.8,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,19F,5.84,7.3,4.67,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,23F,3.74,4.91,2.85,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,148,22F,3.5,4.45,2.75,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,1,2.8,3.49,2.25,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,3,0.51,0.61,0.43,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,4,1.26,1.57,1.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,5,2.61,3.28,2.08,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,6A,3.12,4.3,2.27,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,6B,4.69,6.25,3.52,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,7F,2.45,3.15,1.91,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,9V,2.92,3.57,2.39,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,14,13.68,18.1,10.34,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,18C,3.96,5.09,3.08,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,19A,7.23,9.02,5.8,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,19F,5.19,6.62,4.06,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,23F,3.21,4.25,2.42,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,IgG,0,150,22F,3.94,5.05,3.07,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,1,4.27,5.5,3.31,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,3,0.5,0.6,0.41,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,4,2,2.55,1.56,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,5,2.03,2.64,1.56,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,6A,4.91,6.91,3.49,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,6B,5.23,7.35,3.73,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,7F,3.74,4.81,2.91,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,9V,3.55,4.56,2.77,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,14,15.22,20.03,11.56,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,18C,5.07,6.48,3.97,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,19A,9.61,12.56,7.36,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,19F,6.21,8.15,4.73,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,23F,4.9,6.77,3.54,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,150,22F,0.2,0.25,0.17,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,1,3.16,4.01,2.48,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,3,0.57,0.68,0.48,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,4,1.14,1.44,0.9,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,5,2.38,3.01,1.89,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,6A,5.13,7.04,3.73,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,6B,7.17,9.63,5.34,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,7F,2.61,3.41,2,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,9V,3.35,4.14,2.71,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,14,15.44,20.39,11.69,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,18C,5.58,7.18,4.33,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,19A,9.09,11.67,7.08,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,19F,6.41,8.39,4.89,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,23F,3.92,5.22,2.94,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,IgG,0,152,22F,3.97,5.15,3.06,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,1,200.9,282.7,142.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,3,72.3,89.2,58.6,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,4,1465.5,1860.3,1154.5,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,5,276.7,386.7,197.9,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,6A,5645.1,7447.4,4278.9,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,6B,3554,4591.4,2751,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,7F,6144.3,7576.6,4982.8,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,9V,2133.9,2644.5,1721.8,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,14,3000.3,3830.5,2350,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,18C,1560.3,2005.6,1213.8,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,19A,3715.9,4681.8,2949.2,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,19F,2042,2575.5,1618.9,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,23F,1787,2437.9,1309,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,150,22F,109.3,180.3,66.2,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,1,238.8,329.3,173.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,3,116.8,143.7,94.9,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,4,824,1097.2,618.8,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,5,336.7,467.7,242.4,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,6A,6421,8430.7,4890.4,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,6B,4772.9,6278.7,3628.3,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,7F,6085.8,7602.8,4871.6,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,9V,2836.3,3480.4,2311.5,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,14,3508.7,4508.5,2730.6,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,18C,3002.2,3700.8,2435.5,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,19A,4240.7,5265.3,3415.4,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,19F,2438.6,3014.6,1972.7,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,23F,1757.4,2420.2,1276.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Day 30,OPA,0,152,22F,3943.7,5100.5,3049.2,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,1,154,212.4,111.6,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,3,96.6,117.4,79.5,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,4,984.7,1255.7,772.1,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,5,274.5,376.8,199.9,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,6A,4593.2,5954.7,3543,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,6B,2826.4,3626.8,2202.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,7F,5516.5,6729.5,4522.2,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,9V,1929.9,2375.7,1567.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,14,2539.3,3288.9,1960.6,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,18C,1753.8,2153.1,1428.6,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,19A,3300.3,4127.7,2638.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,19F,1994.1,2438.4,1630.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,23F,1266.5,1698.5,944.3,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,148,22F,2952.7,3949.1,2207.7,PCV13,,Pfizer,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,1,212,280.2,160.5,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,3,102.8,127.2,83,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,4,915.4,1159.1,722.9,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,5,418.1,560.3,312.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,6A,4065.4,5415.1,3052.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,6B,3661.1,4900.6,2735.1,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,7F,5983.5,7476.1,4788.9,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,9V,2454.8,3000,2008.7,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,14,3634,4498.5,2935.6,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,18C,2511.5,3220.3,1958.7,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,19A,3358.1,4208.4,2679.6,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,19F,2230.7,2759,1803.6,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,23F,1641.2,2212.9,1217.2,PCV15,,MSD,0,,0
"North America,Africa,South America,Europe,North America,South America,Asia,Europe,Asia,Africa,Europe,North America,North America","Inclusion Criteria:

Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) <50,000 copies/mL
Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.

Exclusion Criteria:

History of opportunistic infections within 12 months before the first study vaccination
History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy
History of invasive pneumococcal disease
Known hypersensitivity to any vaccine component
Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.",No,All,18 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2),Week 12,OPA,0,150,22F,3399.9,4285,2697.6,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,1,7.86,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,3,0.59,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,4,2.98,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,5,5.21,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,6A,8.22,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,6B,8.35,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,7F,7.82,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,9V,5.39,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,14,11.59,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,18C,10.66,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,19A,16.48,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,19F,10.53,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,23F,6.07,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,325,22F,0.31,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,1,6.97,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,3,1.02,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,4,2.36,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,5,5.43,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,6A,11.48,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,6B,13.69,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,7F,7.14,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,9V,6.1,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,14,12.68,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,18C,16.67,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,19A,18.59,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,19F,12,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,23F,9.76,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,IgG,0,326,22F,5.07,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,1,3.52,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,3,0.28,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,4,1.31,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,5,2.91,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,6A,3.13,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,6B,3.46,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,7F,3.45,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,9V,2.75,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,14,7.5,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,18C,4.32,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,19A,7.22,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,19F,4.14,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,23F,2.66,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,325,22F,0.33,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,1,2.73,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,3,0.39,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,4,1,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,5,2.59,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,6A,4.27,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,6B,5.13,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,7F,2.95,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,9V,2.85,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,14,7.91,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,18C,5.99,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,19A,8.19,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,19F,4.67,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,23F,3.57,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,IgG,0,326,22F,2.07,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,1,296.2,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,3,129.4,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,4,1685.9,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,5,655.9,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,6A,6184.2,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,6B,3631.2,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,7F,5207.6,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,9V,2293,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,14,2458.1,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,18C,2896.3,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,19A,3783,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,19F,2203.5,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,23F,1726.9,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,325,22F,99.6,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,1,361.6,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,3,245.4,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,4,1280.4,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,5,699,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,6A,7352.8,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,6B,5958.1,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,7F,4966.9,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,9V,2329.9,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,14,2677.3,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,18C,4298.2,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,19A,4856.1,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,19F,2418.8,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,23F,2648.7,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Day 30,OPA,0,326,22F,3471.1,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,1,116.2,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,3,56.3,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,4,666.5,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,5,209.6,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,6A,2111.3,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,6B,1453.7,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,7F,2291.1,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,9V,1030.5,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,14,1395.1,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,18C,1191.8,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,19A,1575.3,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,19F,876,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,23F,720.3,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar 13™,OG001,Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,325,22F,99.1,,,PCV13,,Pfizer,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,1,138.2,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,3,88.3,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,4,477.2,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,5,213.4,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,6A,2421.7,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,6B,2079.7,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,7F,2161.8,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,9V,1006.8,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,14,1543.8,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,18C,1520.4,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,19A,1724.3,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,19F,948.4,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,23F,984.7,,,PCV15,,MSD,0,,0
"North America,Asia,North America,Europe,North America,Europe,North America,Europe,North America,,,North America,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female in good health
Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.

Exclusion Criteria

History of invasive pneumococcal disease
Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
Known or suspected impairment of immune function
Coagulation disorder contraindicating intramuscular vaccination
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Female participant: positive urine or serum pregnancy test
Prior administration of any pneumococcal vaccine
Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon steroid injections], and inhaled/nebulized steroids are permitted).
Received immunosuppressive therapy
Received a blood transfusion or blood products within 6 months of enrollment
Participated in another clinical study of an investigational product within 2 months of enrollment
Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.",Accepts Healthy Volunteers,All,50 Years,,"[""Adult"",""Older Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",<time.Time Value>,<time.Time Value>,<time.Time Value>,V114,OG000,Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2).,Month 12,OPA,0,326,22F,1267.4,,,PCV15,,MSD,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,0,210,8,740,915.7,598,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,0,210,1,2604,3234.4,2096.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,1,302,381.4,239.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,3,51,61.2,43.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,4,876,1134.7,676.8,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,5,144,183.2,113.3,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,6A,1907,2436.2,1492.7,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,6B,2006,2527.5,1591.4,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,7F,1581,1836,1361.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,9V,1164,1428,949.6,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,14,1114,1371.4,905,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,18C,1322,1658.9,1053.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,19A,943,1136.1,783.5,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,19F,455,592.2,349.2,PCV20,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or female adults >/= 60 to </=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.
Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
Female subjects who are not of childbearing potential.

Exclusion Criteria:

Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
History of microbiologically proven invasive disease caused by S pneumoniae.
Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]","[""Hispanic or Latino"",""Not Hispanic or Latino"",""Unknown or Not Reported"",""American Indian or Alaska Native"",""Asian"",""Native Hawaiian or Other Pacific Islander"",""Black or African American"",""White"",""More than one race"",""Unknown or Not Reported""]",Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,Pfizer,Pfizer,Interventional,Phase 2,Randomized,Parallel Assignment,Triple,Prevention,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",<time.Time Value>,<time.Time Value>,<time.Time Value>,20vPnC Followed by Saline,OG000,Participants received a single 0.5 milliliter [mL] intramuscular injection of 20-valent pneumococcal conjugate vaccine (20vPnC) (Vaccination 1) on Day 1 followed by 0.5 mL of saline 1 month after Vaccination 1 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1.,1 month after Vaccination 1,OPA,0,210,23F,408,568,293,PCV20,,Pfizer,0,,0
"Europe Asia,Europe Asia","Inclusion Criteria:

Individuals of both sexes from 18 years with a diagnosis of COPD or Bronchial Asthma;
The presence of signed and dated informed consent to participate in a clinical study;
The ability to perform the requirements of the Protocol;
For women of childbearing age is a negative result of a pregnancy test before vaccination.

Diagnostic criteria for:

- COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction.

Exclusion Criteria:

Vaccination against pneumococcal infection in anamnesis;
Application of preparations of immune globulin or blood transfusion within last three months prior to clinical studies;
Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs within 6 months prior to the start of the study;
Any confirmed or suspected immunosuppressive or immunodeficient condition, including Human Immunodeficiency Virus (HIV) infection;
A history or currently hematologic and other cancers;
A positive reaction for HIV infection, viral hepatitis B and hepatitis C;
The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney function, established during a physical examination at visit number 1;
Pronounced congenital defects or serious chronic diseases in the acute stage, including any clinically important exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders, confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver);
Severe allergic reactions in anamnesis, autoimmune disease;
The presence of acute infectious and/or communicable illnesses within 1 month prior to study;
History of chronic alcohol abuse and/or drug use;
Exacerbation of chronic diseases;
Breastfeeding;
Pregnancy;
Participation in any other clinical study within the last 3 months.",Accepts Healthy Volunteers,All,18 Years,80 Years,"[""Adult"",""Older Adult""]",[],Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,Mikhael Petrovich Kostinov,Russian Academy of Medical Sciences,Interventional,Phase 4,Randomized,Parallel Assignment,None (Open Label),Treatment,Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,<time.Time Value>,<time.Time Value>,<time.Time Value>,COPD - Prevenar-13,OG000,32 patients with COPD. Prevenar-13 (PCV13) vaccination.,"Baseline, 1 and 12 months after vaccination",IgG,0,32,Baseline,69.7,113.1,40.9,PCV13,COPD,Pfizer,0,,0
"Europe Asia,Europe Asia","Inclusion Criteria:

Individuals of both sexes from 18 years with a diagnosis of COPD or Bronchial Asthma;
The presence of signed and dated informed consent to participate in a clinical study;
The ability to perform the requirements of the Protocol;
For women of childbearing age is a negative result of a pregnancy test before vaccination.

Diagnostic criteria for:

- COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction.

Exclusion Criteria:

Vaccination against pneumococcal infection in anamnesis;
Application of preparations of immune globulin or blood transfusion within last three months prior to clinical studies;
Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs within 6 months prior to the start of the study;
Any confirmed or suspected immunosuppressive or immunodeficient condition, including Human Immunodeficiency Virus (HIV) infection;
A history or currently hematologic and other cancers;
A positive reaction for HIV infection, viral hepatitis B and hepatitis C;
The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney function, established during a physical examination at visit number 1;
Pronounced congenital defects or serious chronic diseases in the acute stage, including any clinically important exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders, confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver);
Severe allergic reactions in anamnesis, autoimmune disease;
The presence of acute infectious and/or communicable illnesses within 1 month prior to study;
History of chronic alcohol abuse and/or drug use;
Exacerbation of chronic diseases;
Breastfeeding;
Pregnancy;
Participation in any other clinical study within the last 3 months.",Accepts Healthy Volunteers,All,18 Years,80 Years,"[""Adult"",""Older Adult""]",[],Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,Mikhael Petrovich Kostinov,Russian Academy of Medical Sciences,Interventional,Phase 4,Randomized,Parallel Assignment,None (Open Label),Treatment,Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,<time.Time Value>,<time.Time Value>,<time.Time Value>,COPD - Prevenar-13,OG000,32 patients with COPD. Prevenar-13 (PCV13) vaccination.,"Baseline, 1 and 12 months after vaccination",IgG,0,32,6 months after vaccination,132.7,179.9,88.9,PCV13,COPD,Pfizer,0,,0
"Europe Asia,Europe Asia","Inclusion Criteria:

Individuals of both sexes from 18 years with a diagnosis of COPD or Bronchial Asthma;
The presence of signed and dated informed consent to participate in a clinical study;
The ability to perform the requirements of the Protocol;
For women of childbearing age is a negative result of a pregnancy test before vaccination.

Diagnostic criteria for:

- COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction.

Exclusion Criteria:

Vaccination against pneumococcal infection in anamnesis;
Application of preparations of immune globulin or blood transfusion within last three months prior to clinical studies;
Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs within 6 months prior to the start of the study;
Any confirmed or suspected immunosuppressive or immunodeficient condition, including Human Immunodeficiency Virus (HIV) infection;
A history or currently hematologic and other cancers;
A positive reaction for HIV infection, viral hepatitis B and hepatitis C;
The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney function, established during a physical examination at visit number 1;
Pronounced congenital defects or serious chronic diseases in the acute stage, including any clinically important exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders, confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver);
Severe allergic reactions in anamnesis, autoimmune disease;
The presence of acute infectious and/or communicable illnesses within 1 month prior to study;
History of chronic alcohol abuse and/or drug use;
Exacerbation of chronic diseases;
Breastfeeding;
Pregnancy;
Participation in any other clinical study within the last 3 months.",Accepts Healthy Volunteers,All,18 Years,80 Years,"[""Adult"",""Older Adult""]",[],Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,Mikhael Petrovich Kostinov,Russian Academy of Medical Sciences,Interventional,Phase 4,Randomized,Parallel Assignment,None (Open Label),Treatment,Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology,<time.Time Value>,<time.Time Value>,<time.Time Value>,COPD - Prevenar-13,OG000,32 patients with COPD. Prevenar-13 (PCV13) vaccination.,"Baseline, 1 and 12 months after vaccination",IgG,0,32,2,112.9,157.1,69.2,PCV13,COPD,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,1,18.89,45.59,10.14,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,5,263.06,499.28,138.91,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,6A,17161.52,23946.2,12378.36,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,6B,13303.68,18190.05,9432.51,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,7F,7099.73,11222.44,4147.2,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,9V,3928.12,5629.89,2827.41,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,14,9148.12,12407.65,6271.81,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,19A,3170.33,4427.88,1906.55,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,19F,3564.32,4898.79,2636.19,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,23F,5035.73,7587.87,3417.87,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,1,50.65,96.55,27.91,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,5,113.92,167.1,74.12,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,6A,1243.88,1834.3,942.4,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,6B,1530.37,2368.41,935.24,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,7F,876.58,1221.31,616.9,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,9V,197.24,347.56,95.09,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,14,1243.39,1912.05,743.97,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,19A,151.31,233.45,64.25,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,19F,744.92,941.74,607.87,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG004,"Dose of SIILPCV 10 on Days 0, 28 & 56",4 weeks after last vaccination,OPA,0,20,23F,627.27,975.77,341.95,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,1,29.42,68.08,15.58,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,5,104.83,181.22,64.11,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,6A,3068.16,5318.41,2267.85,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,6B,2267.44,3718.87,1175.92,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,7F,3763.17,5393.72,2754.89,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,9V,752.77,1024.26,528.18,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,14,1108.02,2097.51,501.79,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,19A,765.71,886.28,589.49,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,19F,498.98,723.41,275.77,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG005,"Dose of Prevenar 13 on Days 0, 28, & 56",4 weeks after last vaccination,OPA,0,20,23F,921.43,1419.94,574.79,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,1,436.31,582.46,365.08,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,5,1358.22,2087.48,960.34,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,6A,19371.45,34268.51,12538.18,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,6B,8768.08,12932.67,5471.57,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,7F,10723.98,16590.09,7151.48,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,9V,3770.19,6384.49,2004.45,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,14,8213.23,13664.12,4526.63,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,19A,1789.98,3498.32,651.04,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,19F,3036.6,5126.44,2134.81,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG002,Single dose of SIILPCV 10 on Day 0,4 weeks after last vaccination,OPA,0,17,23F,12415.92,19342.91,8018.97,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,1,438.14,890.17,278.73,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,5,1148.43,1708.67,929.92,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,6A,12001.09,21545.31,8229.26,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,6B,7066.76,11894.25,4456.49,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,7F,12737.21,18328.98,8063.57,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,9V,4862.3,6953.05,3128.56,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,14,2557.27,3868.34,1597.17,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,19A,3780.56,6045.56,2358.04,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,19F,3371.52,5853.53,2238.81,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG003,Single dose of Prevenar 13 on Day 0,4 weeks after last vaccination,OPA,0,17,23F,10517.81,19460.6,5848.87,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,1,2.99,3.43,2.61,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,5,2.09,2.36,1.86,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,6A,1.02,1.27,0.83,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,6B,1.57,1.92,1.28,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,7F,2.19,2.53,1.89,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,9V,1.07,1.23,0.93,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,14,4.96,5.87,4.2,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,19A,1.49,1.76,1.26,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,19F,3.87,4.49,3.35,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--PCV 10,OG000,"Dose of SIILPCV 10 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,23F,1.56,1.83,1.32,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,1,3.38,3.78,3.02,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,5,1.74,1.98,1.53,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,6A,1.82,2.17,1.53,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,6B,3.64,4.42,3.01,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,7F,3.88,4.38,3.44,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,9V,2.19,2.5,1.91,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,14,4.47,5.53,3.62,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,19A,5.2,6.2,4.37,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,19F,5.38,6.05,4.79,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Infant--Prevenar 13,OG001,"Dose of Prevenar 13 on Day 0, 28 and 56",4 weeks after the third dose,IgG,3,100,23F,2.68,3.15,2.28,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--PCV 10,OG000,Dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,56,1,0.77,1.36,0.46,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Toddler--Prevenar 13,OG001,Dose of Prevenar 13 on Day 0,4 weeks after vaccination,IgG,0,56,1,0.92,1.26,0.72,PCV13,,Pfizer,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,1,3.96,6.24,2.51,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,5,3.56,6.01,2.11,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,6A,17.09,30.29,9.64,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,6B,26.87,47.36,15.24,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,7F,4.62,6.2,3.44,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,9V,4.92,7.03,3.45,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,14,48.23,73.62,31.6,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,19A,19.47,31.25,12.13,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,19F,20.72,29.37,14.62,PCV10 (Pneumosil),,Serum Institute of India,0,,0
Africa,"Inclusion Criteria:

• Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg

Able to provide informed consent (for themselves or child)
Willing to comply with study requirements and procedures.
Toddlers have completed their Gambian infant EPI schedule
Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.
Infants and toddlers with a weight-to-height Z score of ≥ -2.
Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.

Exclusion Criteria:

Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.
Ingestion of herbal or other traditional local medication within 14 days of randomization.
Adults and infants who have previously been vaccinated against S. pneumoniae.
History of S. pneumoniae infection confirmed by culture from a normally sterile site.
History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
History of anaphylactic shock.
Screening laboratory test or vital signs outside the normal range.
HIV-positive or HbsAg- positive based on testing during screening.
Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).
Use of antibiotics within 5 days of randomization (excluding treatment for malaria).
A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).
Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.
Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.
History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.
Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.

Adults only

Recent history or signs of alcohol or substance abuse.
History of major psychiatric disorder.
Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only
Family history of suspected primary immunodeficiency in first-degree relative.
Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.
Evidence of a clinically significant congenital abnormality as judged by the PI.
Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.
History of meningitis, seizures or any neurological disorder.
Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms",Accepts Healthy Volunteers,All,,40 Years,"[""Child"",""Adult""]","[""African"",""Asian"",""Other"",""Mandinka"",""Wolof"",""Fula"",""Jola"",""Serahule"",""Serere"",""Manjago"",""Other""]","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",PATH,PATH,Interventional,"Phase 1, Phase 2",Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants",<time.Time Value>,<time.Time Value>,<time.Time Value>,Adults--PCV 10,OG000,Single dose of SIILPCV 10 on Day 0,4 weeks after vaccination,IgG,0,17,23F,10.09,16.24,6.26,PCV10 (Pneumosil),,Serum Institute of India,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,3,103,125.5,84.6,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,5,44,51.5,38.1,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,4,1016,1213.2,850.7,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,3,103,125.5,84.6,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,5,44,51.5,38.1,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
Previous vaccination with any licensed or experimental pneumococcal vaccine.
Documented Streptococcus pneumoniae infection within the past 5 years.
Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.",Accepts Healthy Volunteers,All,65 Years,,"[""Older Adult""]",[],"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older",Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.,One month after vaccination,OPA,0,366,4,1016,1213.2,850.7,PCV13,,Pfizer,0,,0
"North America,North America,North America","Inclusion Criteria:

Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
A male or female between, and including, 6-12 weeks of age at the time of the first vaccination.
Healthy subjects as established by medical history and clinical examination before entering into the study.
Born after a gestation period of at least 36 weeks.
Written informed consent obtained from the parent(s)/LAR(s) of the subject.

Exclusion Criteria:

Child in care.
Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the entire study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth or planned use during the study.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
Major congenital defects or serious chronic illness.
History of any seizures or progressive neurological disease.
Administration of immunoglobulins and/or blood products since birth or planned use during the study.
Acute disease and/or fever at the time of enrolment.
Previous vaccination or planned vaccination during the study with any pneumococcal vaccine.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]",[],Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™,<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix Group,OG000,"Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",IgG,2,86,1,0.34,0.4,0.29,PCV10 (Synflorix),,GSK,0,,0
"North America,North America,North America","Inclusion Criteria:

Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
A male or female between, and including, 6-12 weeks of age at the time of the first vaccination.
Healthy subjects as established by medical history and clinical examination before entering into the study.
Born after a gestation period of at least 36 weeks.
Written informed consent obtained from the parent(s)/LAR(s) of the subject.

Exclusion Criteria:

Child in care.
Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the entire study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth or planned use during the study.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
Major congenital defects or serious chronic illness.
History of any seizures or progressive neurological disease.
Administration of immunoglobulins and/or blood products since birth or planned use during the study.
Acute disease and/or fever at the time of enrolment.
Previous vaccination or planned vaccination during the study with any pneumococcal vaccine.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]",[],Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™,<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix Group,OG000,"Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",IgG,2,86,3,2.74,3.24,2.32,PCV10 (Synflorix),,GSK,0,,0
"North America,North America,North America","Inclusion Criteria:

Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
A male or female between, and including, 6-12 weeks of age at the time of the first vaccination.
Healthy subjects as established by medical history and clinical examination before entering into the study.
Born after a gestation period of at least 36 weeks.
Written informed consent obtained from the parent(s)/LAR(s) of the subject.

Exclusion Criteria:

Child in care.
Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the entire study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth or planned use during the study.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
Major congenital defects or serious chronic illness.
History of any seizures or progressive neurological disease.
Administration of immunoglobulins and/or blood products since birth or planned use during the study.
Acute disease and/or fever at the time of enrolment.
Previous vaccination or planned vaccination during the study with any pneumococcal vaccine.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]",[],Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™,<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix Group,OG000,"Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",OPA,2,45,1,10.3,13.2,8.1,PCV10 (Synflorix),,GSK,0,,0
"North America,North America,North America","Inclusion Criteria:

Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
A male or female between, and including, 6-12 weeks of age at the time of the first vaccination.
Healthy subjects as established by medical history and clinical examination before entering into the study.
Born after a gestation period of at least 36 weeks.
Written informed consent obtained from the parent(s)/LAR(s) of the subject.

Exclusion Criteria:

Child in care.
Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the entire study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth or planned use during the study.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
Major congenital defects or serious chronic illness.
History of any seizures or progressive neurological disease.
Administration of immunoglobulins and/or blood products since birth or planned use during the study.
Acute disease and/or fever at the time of enrolment.
Previous vaccination or planned vaccination during the study with any pneumococcal vaccine.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]",[],Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™,<time.Time Value>,<time.Time Value>,<time.Time Value>,Synflorix Group,OG000,"Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",OPA,2,45,3,58.9,87.9,39.4,PCV10 (Synflorix),,GSK,0,,0
"North America,North America,North America,North America,North America","Inclusion Criteria:

Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol.
A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.
Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
Healthy subject as established by medical history and clinical examination before entering into the study.
Born after a gestation period of more than 35 6/7 weeks.

Exclusion Criteria:

For all infants:

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous vaccination against S. pneumoniae.
Obstruction or anomalies of the nasopharyngeal space.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Family history of congenital or hereditary immunodeficiency.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including latex.
Major congenital defects or serious chronic illness.
History of any neurological disorders or seizures.
Acute disease and/or fever at the time of enrollment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Any medical or social condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

For infants in the Immuno/reacto subgroup only:

• Previous vaccination against H. influenzae type b.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]","[""American indian or Alaskan native""]",Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 2,Randomized,Parallel Assignment,Quadruple,Prevention,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,<time.Time Value>,<time.Time Value>,<time.Time Value>,Control Group,OG001,"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age. PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months. At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate. At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate.","One month post-dose 3 [PIII(Month 5)], prior to booster dose [PIII(Month 10)] and one month post-booster dose [Post-booster(Month 11)]",IgG,0,118,5,3.18,3.62,2.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America","Inclusion Criteria:

Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol.
A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.
Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
Healthy subject as established by medical history and clinical examination before entering into the study.
Born after a gestation period of more than 35 6/7 weeks.

Exclusion Criteria:

For all infants:

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous vaccination against S. pneumoniae.
Obstruction or anomalies of the nasopharyngeal space.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Family history of congenital or hereditary immunodeficiency.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including latex.
Major congenital defects or serious chronic illness.
History of any neurological disorders or seizures.
Acute disease and/or fever at the time of enrollment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Any medical or social condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

For infants in the Immuno/reacto subgroup only:

• Previous vaccination against H. influenzae type b.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]","[""American indian or Alaskan native""]",Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 2,Randomized,Parallel Assignment,Quadruple,Prevention,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,<time.Time Value>,<time.Time Value>,<time.Time Value>,Control Group,OG001,"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age. PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months. At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate. At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate.","One month post-dose 3 [PIII(Month 5)], prior to booster dose [PIII(Month 10)] and one month post-booster dose [Post-booster(Month 11)]",IgG,0,118,1,0.55,0.62,0.49,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America","Inclusion Criteria:

Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol.
A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.
Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
Healthy subject as established by medical history and clinical examination before entering into the study.
Born after a gestation period of more than 35 6/7 weeks.

Exclusion Criteria:

For all infants:

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous vaccination against S. pneumoniae.
Obstruction or anomalies of the nasopharyngeal space.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Family history of congenital or hereditary immunodeficiency.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including latex.
Major congenital defects or serious chronic illness.
History of any neurological disorders or seizures.
Acute disease and/or fever at the time of enrollment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Any medical or social condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

For infants in the Immuno/reacto subgroup only:

• Previous vaccination against H. influenzae type b.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]","[""American indian or Alaskan native""]",Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 2,Randomized,Parallel Assignment,Quadruple,Prevention,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,<time.Time Value>,<time.Time Value>,<time.Time Value>,Control Group,OG001,"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age. PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months. At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate. At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate.",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,0,59,5,32.9,53.7,20.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America","Inclusion Criteria:

Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol.
A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.
Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
Healthy subject as established by medical history and clinical examination before entering into the study.
Born after a gestation period of more than 35 6/7 weeks.

Exclusion Criteria:

For all infants:

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous vaccination against S. pneumoniae.
Obstruction or anomalies of the nasopharyngeal space.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Family history of congenital or hereditary immunodeficiency.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including latex.
Major congenital defects or serious chronic illness.
History of any neurological disorders or seizures.
Acute disease and/or fever at the time of enrollment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Any medical or social condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

For infants in the Immuno/reacto subgroup only:

• Previous vaccination against H. influenzae type b.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]","[""American indian or Alaskan native""]",Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 2,Randomized,Parallel Assignment,Quadruple,Prevention,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,<time.Time Value>,<time.Time Value>,<time.Time Value>,Control Group,OG001,"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age. PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months. At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate. At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate.",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,0,59,1,219.7,358.5,134.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America","Inclusion Criteria:

Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol.
A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.
Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
Healthy subject as established by medical history and clinical examination before entering into the study.
Born after a gestation period of more than 35 6/7 weeks.

Exclusion Criteria:

For all infants:

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous vaccination against S. pneumoniae.
Obstruction or anomalies of the nasopharyngeal space.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Family history of congenital or hereditary immunodeficiency.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s) including latex.
Major congenital defects or serious chronic illness.
History of any neurological disorders or seizures.
Acute disease and/or fever at the time of enrollment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Any medical or social condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

For infants in the Immuno/reacto subgroup only:

• Previous vaccination against H. influenzae type b.",Accepts Healthy Volunteers,All,6 Weeks,12 Weeks,"[""Child""]","[""American indian or Alaskan native""]",Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,GlaxoSmithKline,GlaxoSmithKline,Interventional,Phase 2,Randomized,Parallel Assignment,Quadruple,Prevention,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,<time.Time Value>,<time.Time Value>,<time.Time Value>,Control Group,OG001,"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age. PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months. At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate. At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate.",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,0,54,6C,2616.6,3558.2,1924.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,1,220,269.3,178.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,6B,2012,2574.1,1571.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,19F,696,887.7,546.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,23F,358,481.7,265.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,3,74,88.7,61.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,19A,696,833.6,581.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,4,2517,3029.2,2091.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,7F,1252,1614.4,971.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,9V,758,1018.9,563.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,5,227,300.5,170.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,18C,1532,1982.7,1183.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,221,14,664,908.5,485.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,19A,709,811.2,618.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,18C,1576,1880.9,1321.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,9V,767,949.3,620,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,4,2536,2933,2192.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,7F,1063,1302.2,868.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,1,207,240.9,177.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,19F,711,848.9,595.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,14,650,805.8,524.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,6B,1948,2351.7,1614,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,23F,354,440.7,283.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,5,215,261.7,175.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,455,3,75,85.3,66,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,6A,2682,3652.1,1969.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,4,2255,3128.6,1625.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,9V,919,1364,619.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,14,492,774.5,312.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,7F,930,1437.1,602.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,6B,2112,2958.2,1508,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,23F,291,452.2,187.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,3,73,94.1,57.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,1,215,282.4,163.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,5,170,258.6,112.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,18C,1440,2043.5,1015.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,19F,566,829.2,385.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female, aged 60 to 64 years.
Healthy.

Exclusion Criteria:

Previous vaccination with any licensed or experimental pneumococcal vaccine.
History of severe adverse reaction associated with a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,60 Years,64 Years,"[""Adult""]",[],"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Crossover Assignment,Triple,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Vaccination 1 (Year 0),OG000,13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.,1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,0,127,19A,583,796.8,426.6,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,421,6A,903,1121.3,726.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,1,76,89.5,64.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,3,55,62,47.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,4,472,580.2,383.5,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,5,56,67.7,46.6,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,6B,1565,1875.9,1306.1,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,7F,185,239.7,142.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,9V,158,209.5,119.5,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,14,238,293.8,192.3,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,18C,975,1147.3,829,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,19A,339,386.9,296.4,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,19F,311,375.9,257.1,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC / 13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,370,23F,310,378,254.1,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,1,81,95.9,68.4,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,3,55,62.9,47.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,4,545,672.3,441.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,5,72,86.6,59.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,6B,1261,1552.6,1024.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,7F,245,312.4,191.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,9V,181,237,138,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,14,280,345.5,227.5,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,18C,907,1080.1,761.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,19A,354,408.4,307.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,19F,333,404.8,273.2,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),1 month after Vax 1 / Year 0,OPA,0,426,23F,158,198.6,126,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,1,79,94.6,65.3,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,3,55,64,47.2,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,4,614,768.8,489.8,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,5,69,84.2,56.2,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,6A,971,1222.1,771,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,6B,1358,1700.2,1085.4,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,7F,222,290.2,170.2,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,9V,187,250.4,139.3,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,14,265,333.6,209.9,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,18C,918,1104.3,763.4,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,19A,349,405.5,299.7,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,19F,329,408.6,265.6,PCV13,,Pfizer,0,,0
"Europe,North America,North America,Europe,North America,Europe,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Male or Female aged 70 years or older.
Documented vaccination with 1 dose of 23vPS at least 5 years previous.
Healthy.

Exclusion Criteria:

Receipt of more than one dose of 23vPS prior to enrollment.
History of severe adverse reaction to a vaccine.
Immunodeficiency.",Accepts Healthy Volunteers,All,70 Years,,"[""Older Adult""]",[],"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,13vPnC 0.5 mL dose IM at Year 0 (Vax 1),"1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1",OPA,0,361,23F,167,213,130.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,4,1.46,1.6,1.33,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,6B,2.16,2.49,1.87,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,9V,1.12,1.22,1.03,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,14,5.43,6.06,4.86,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,18C,1.37,1.52,1.23,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,19F,2.18,2.39,1.99,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,23F,1.15,1.3,1.03,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,2,1.82,2.04,1.63,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the 3-dose infant series (7 months of age),IgG,0,300,5,0.63,0.7,0.58,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,4,2.67,2.92,2.43,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,6B,9.83,10.94,8.83,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,9V,2.04,2.23,1.87,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,14,7.58,8.37,6.86,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,18C,2,2.21,1.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,19F,5.7,6.42,5.06,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month old infants (42 to 98 days)
Available for the duration of the study and reachable by telephone

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccine
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding disorder, immune deficiency or suppression, or significant chronic or congenital disease
Receipt of blood products or gamma globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Subjects received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose). Co-administered with Pentacel® (a commercially available combination diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b [Hib] conjugate vaccine ) at 2, 4, and 6 months of age; NeisVac-C® (a commercially available meningococcal C tetanus toxoid conjugate vaccine) at 2 and 6 months of age (infant series) and 12 months of age (toddler dose); a single type Measles, Mumps, and Rubella vaccine (MMR) at 12 months; and a single type of commercially available varicella vaccine at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,287,23F,3.59,4.01,3.21,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,4,1.55,1.78,1.35,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,6B,0.21,0.25,0.18,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,9V,1.15,1.32,1.01,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,14,1.94,2.29,1.64,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,18C,1.3,1.51,1.11,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,19F,2.98,3.41,2.6,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,23F,0.4,0.48,0.34,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,1,1.87,2.16,1.61,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,3,0.54,0.61,0.48,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,5,0.88,1,0.77,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,6A,0.81,0.95,0.7,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,7F,1.51,1.71,1.33,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix hexa at the 2- and 4-month visits (infant series Dose 2).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,206,19A,1.52,1.76,1.31,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,4,2.32,2.6,2.08,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,6B,2.59,3.05,2.2,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,9V,1.51,1.68,1.35,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,14,4.51,5.22,3.89,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,18C,1.86,2.07,1.68,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,19F,2.46,2.74,2.21,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,23F,1.67,1.94,1.44,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,1,2.95,3.33,2.61,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,3,0.85,0.95,0.76,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,5,1.83,2.06,1.62,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,6A,3.08,3.44,2.76,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,7F,3.41,3.74,3.11,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at the 6-month visit (infant series dose 3).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,1,197,19A,2.5,2.75,2.27,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,4,3.88,4.4,3.42,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,6B,12.25,13.92,10.78,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,9V,2.67,3.05,2.34,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,14,9.82,11.3,8.54,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,18C,2.29,2.61,2.01,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,19F,6.11,7.16,5.21,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,23F,3.96,4.59,3.43,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,1,4.6,5.37,3.94,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,3,1.04,1.19,0.91,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,5,3.69,4.18,3.26,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,6A,7.71,8.8,6.75,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,7F,5.66,6.53,4.9,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Infanrix IPV + Hib at the 15-month visit (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,212,19A,10.21,11.68,8.92,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

Post-bronchodilator forced expiratory volume at one second

/forced vital capacity (FEV1/FVC) level less than 70%

Ten or more pack-years of smoking
Willing to make return visits to the study clinic and accept telephone contact
Last pneumococcal vaccination occured at least 5 years prior to study entry

Exclusion Criteria:

Asthma
Sensitivity to pneumococcal vaccine
Known bleeding disorder, or requires long-term anticoagulation therapy
Presence of chronic disease that may impair pneumococcal vaccine response
Acute illness requiring antibiotics in the month prior to study entry
Medical condition that makes survival for 24 months following study entry unlikely
Pregnant",Accepts Healthy Volunteers,All,40 Years,,"[""Adult"",""Older Adult""]","[""Caucasian"",""African American"",""Asian"",""Native American"",""Pacific Islander"",""More than one""]",Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease,University of Minnesota,University of Minnesota,Interventional,Phase 3,Randomized,Parallel Assignment,None (Open Label),Prevention,Pneumococcal Vaccine Response in COPD,<time.Time Value>,<time.Time Value>,<time.Time Value>,Prevnar (PCV7),OG001,diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose,"Measured at Baseline, Months 1, 12, and 24",IgG,0,91,4,0.28,0.37,0.21,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,4,5.33,6.04,4.69,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,6B,12.24,14.13,10.6,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,9V,3.01,3.37,2.68,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,14,10.59,12.18,9.21,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,18C,2.63,2.97,2.33,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,19F,8.38,9.87,7.11,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,23F,4.27,4.98,3.66,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,4,193,3,5.1,5.92,4.39,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,4,5.85,6.68,5.13,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,6B,11.6,13.53,9.95,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,9V,3.33,3.75,2.96,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,14,10.95,12.74,9.41,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,18C,2.98,3.34,2.65,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,19F,5.65,6.58,4.84,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,23F,5.31,6.04,4.66,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after toddler dose (13 months of age),IgG,1,196,3,0.04,0.05,0.04,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,4,2.19,2.46,1.95,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,6B,1.45,1.75,1.2,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,9V,1.34,1.5,1.19,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,14,2.84,3.43,2.35,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,18C,1.61,1.82,1.42,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,19F,2.25,2.56,1.97,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,23F,1.38,1.6,1.18,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC), administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 13vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,3,206,5,1.95,2.22,1.72,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,4,2.58,2.95,2.26,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,6B,1.56,1.89,1.28,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,9V,1.46,1.65,1.28,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,14,2.39,2.9,1.98,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,18C,1.7,1.96,1.47,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,19F,2.47,2.89,2.11,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,23F,1.46,1.7,1.25,PCV7,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria

Healthy infants aged 6 weeks (42-72 days) at time of enrolment
Available for the entire study period

Exclusion Criteria

Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
A previous anaphylactic reaction to any vaccine or vaccine-related component
Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines",Accepts Healthy Volunteers,All,42 Days,72 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series) and 12 months of age (toddler dose). During the infant series, 7vPnC was co-administered with a commercially available combination vaccine containing: diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).",1 month after the 3-dose infant series (18 weeks of age),IgG,1,196,5,0.03,0.04,0.03,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,8,1.75,1.88,1.63,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,6B,2.54,2.85,2.27,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,9V,1.11,1.19,1.04,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,14,5.18,5.69,4.72,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,18C,1.48,1.58,1.38,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,19F,2.59,2.78,2.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,23F,1.03,1.14,0.94,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,5,1.91,2.07,1.76,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,2,427,4,0.61,0.66,0.57,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,8,1.33,1.43,1.24,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,6B,2.89,3.23,2.58,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,9V,1.05,1.12,0.98,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,14,4.97,5.37,4.59,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,18C,1.3,1.38,1.22,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,19F,1.85,1.99,1.71,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,23F,1.24,1.36,1.13,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,5,1.62,1.76,1.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,0,435,4,0.52,0.55,0.48,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,8,1.34,1.44,1.25,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,6B,2.15,2.42,1.91,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,9V,1.11,1.19,1.04,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,14,5.13,5.59,4.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,18C,1.34,1.44,1.24,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,19F,2.07,2.24,1.92,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,23F,1.27,1.4,1.15,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,5,1.81,1.98,1.66,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 Month after the infant series (7 Months of age),IgG,1,427,4,0.56,0.61,0.52,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,5,3.06,3.35,2.79,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,8,9.92,10.75,9.15,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,9V,1.99,2.15,1.84,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,14,6.91,7.56,6.32,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,18C,2.48,2.71,2.27,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,19F,6.51,7.18,5.91,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Manufacturing Lot),OG002,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,2,408,23F,3.1,3.43,2.81,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,5,2.29,2.48,2.11,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,8,11.14,12.11,10.24,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,9V,1.91,2.06,1.76,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,14,6.61,7.22,6.06,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,18C,1.95,2.12,1.78,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,19F,4.51,5.03,4.05,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 1),OG000,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,0,415,23F,3.35,3.71,3.02,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,5,2.25,2.44,2.07,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,8,9.33,10.19,8.55,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,9V,1.95,2.1,1.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,14,7.05,7.74,6.42,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,18C,2.2,2.41,2.01,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,19F,4.67,5.14,4.23,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion criteria:

Healthy 2 month old infants
Available for the duration of the study and reachable by telephone
Able to complete two blood drawing procedures during the study

Exclusion criteria:

Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
Bleeding disorder, immune deficiency or significant chronic or congenital disease
Previous receipt of blood products or immune globulin",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC (Pilot Lot 2),OG001,"Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.",1 month after the toddler dose (13 months of age),IgG,1,397,23F,3.46,3.82,3.14,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,23F,375,472.6,297.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,6A,2593,3131.1,2146.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,18C,1726,2082.9,1429.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,4,2062,2510.5,1693.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,9V,1164,1448.3,934.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,3,93,106.6,81.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,5,199,242.3,164,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,19A,682,779.9,596.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,19F,517,635.3,420.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,1,146,172.9,124,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,7F,1120,1382.9,907.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,6B,1984,2453.6,1604,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 1",OG000,Participants 60-64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly (Vaccination 1 [Vax1]).,One month after vaccination 1,OPA,0,411,14,612,764.2,489.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,18C,1939,2350.2,1599.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,19A,956,1090.7,837.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,4,2833,3327.4,2412.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,3,91,104.7,79.9,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,9V,1726,2086.2,1428.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,5,269,332.5,218.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,7F,1520,1812.1,1274.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,14,957,1174.5,779.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,6B,3212,3781.4,2728.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,19F,599,731,491,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,6A,4328,5121.5,3658.1,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,1,200,236,170.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 2",OG002,Participants 50-59 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly at (Vaccination 1).,One month after vaccination 1,OPA,0,388,23F,494,630.7,386.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,19A,1580,1696.3,1471.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,23F,1570,1770.2,1392.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,7F,3249,3523.9,2994.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,14,2983,3246.6,2740.5,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,6B,9813,10583.5,9097.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,6A,5746,6300.4,5240.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,18C,3989,4383.8,3629.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,9V,3339,3670.4,3037.4,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,1,353,386.9,322.8,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,5,386,435.8,342.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,3,91,98.4,84.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,19F,1533,1680.9,1397.3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion Criteria:

Previous immunization with any licensed or experimental pneumococcal vaccine.
Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
Known or suspected impairment of immunological function.",Accepts Healthy Volunteers,All,18 Years,64 Years,"[""Adult""]",[],Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pfizer,Pfizer,Interventional,Phase 3,Randomized,,Quadruple,Prevention,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",<time.Time Value>,<time.Time Value>,<time.Time Value>,"13vPnC, Cohort 3",OG003,Participants 18-49 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly (Vaccination 1).,One month after vaccination 1,OPA,0,874,4,4747,5155.5,4370.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,5,3.73,4.24,3.28,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,6B,11.53,13.3,9.99,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,9V,2.62,2.94,2.32,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,14,9.11,10.45,7.95,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,18C,3.2,3.64,2.82,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,19F,6.6,7.44,5.85,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,0,239,23F,5.07,5.83,4.41,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,5,5.49,6.13,4.91,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,6B,15.63,17.69,13.8,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,9V,3.63,4.05,3.25,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,14,12.72,14.41,11.22,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,18C,4.7,5.28,4.18,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,19F,5.6,6.43,4.87,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC,OG001,"Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with Haemophilus b Conjugate Vaccine (ActHIB) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined (Pediarix) at 2, 4, 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with measles, mumps, rubella varicella vaccine live (ProQuad), Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB), and Hepatitis A Vaccine, Inactivated (VAQTA) at 12-15 months of age (toddler dose).",1 Month After the Toddler Dose,IgG,1,223,23F,7.84,8.9,6.91,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,8,359.32,467.72,276.04,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,6B,1054.65,1360.87,817.34,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,9V,4035.4,5552.75,2932.68,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,14,1240.41,1645.69,934.93,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,18C,275.59,361.1,210.33,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,19F,54.42,73.65,40.2,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Infant Series,OG000,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,0,252,23F,791.07,1034.44,604.96,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,8,1179.98,1643.2,847.34,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,6B,3099.51,4110.79,2337.02,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,9V,11856.03,15955.49,8809.85,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,14,2002.23,2759.93,1452.54,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,18C,993.27,1308.33,754.08,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,19F,199.65,276.38,144.22,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,"Subjects received 1 single 0.5 mL dose of 13vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,2,239,23F,2723.25,3782.41,1960.67,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,8,535.68,681.37,421.13,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,6B,1513.66,1898.81,1206.64,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,9V,3259.01,4641.25,2288.43,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,14,1480.55,1934.02,1133.4,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,18C,375.64,483.75,291.68,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,19F,44.92,59.52,33.9,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Infant Series,OG001,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,1,252,23F,923.56,1203.74,708.59,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,8,1492.46,1998.78,1114.4,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,6B,4066.22,5097.76,3243.42,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,9V,18032.33,23020.53,14124.99,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,14,2365.87,2992.34,1870.56,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,18C,1722.16,2235.67,1326.59,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,19F,167.2,230.37,121.35,PCV7,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study.
Known contraindication to vaccination.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Pfizer,Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After the Toddler Dose,OG003,"Subjects received 1 single 0.5 mL dose of 7vPnC coadministered with Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.",one month after the infant series and the toddler dose,OPA,3,223,23F,4981.68,6386.76,3885.71,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,4,1.89,2.1,1.7,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,8,0.42,0.47,0.37,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,9V,1.49,1.66,1.34,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,14,3.84,4.37,3.37,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,18C,1.58,1.78,1.4,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,19F,2.85,3.21,2.53,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 2,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,2,297,23F,0.54,0.62,0.47,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,4,2.33,2.57,2.11,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,8,3.88,4.41,3.41,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,9V,1.71,1.86,1.56,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,14,6.17,6.98,5.45,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,18C,2.29,2.52,2.08,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,19F,2.64,2.89,2.42,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series Dose 3,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,3,293,23F,2.15,2.45,1.89,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,4,4.97,5.58,4.42,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,8,11.88,13.35,10.57,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,9V,3.44,3.8,3.12,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,14,11.37,12.71,10.17,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,18C,3.96,4.43,3.55,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,19F,8.04,9.14,7.07,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants
Available for the entire study period

Exclusion criteria:

Previous vaccination with any vaccine before the start of the study
Known contraindication to vaccination",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Double,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After the Toddler Dose,OG002,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).,One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),IgG,4,275,23F,5.07,5.71,4.5,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,4,526.69,642.32,431.88,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,6B,191.34,274.55,133.35,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,9V,3585.8,4612.99,2787.34,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,14,1882.96,2451.1,1446.51,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,18C,294.48,390.98,221.8,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,19F,222.86,291.37,170.46,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,23F,487.51,667.13,356.25,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,1,62.63,82.41,47.59,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,3,176.07,213.96,144.89,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,5,127.11,162.6,99.36,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,6A,541.81,748.68,392.09,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,one month after infant series dose 2 and after the toddler dose,OPA,2,100,7F,5914.33,7425.3,4710.83,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,4,1276.21,1588.85,1025.09,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,6B,2383.31,3069.57,1850.47,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,9V,16384,20543.06,13066.97,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,14,1903.89,2292.88,1580.9,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,18C,1324.41,1649.22,1063.57,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,19F,391.97,518.46,296.34,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,23F,3679.67,4556.44,2971.61,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,1,294.07,381.15,226.88,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,3,504.66,584.53,435.71,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,5,333.24,404.94,274.24,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,6A,2217.29,2698.42,1821.95,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG001,Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,one month after infant series dose 2 and after the toddler dose,OPA,4,100,7F,14886.35,17643.22,12560.25,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,4,2.38,2.67,2.11,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,6B,0.41,0.47,0.36,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,9V,1.68,1.86,1.51,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,14,2.84,3.31,2.44,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,18C,1.72,1.93,1.54,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,19F,3.42,3.97,2.95,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,23F,0.61,0.71,0.53,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,1,2.3,2.6,2.03,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,3,1.15,1.28,1.04,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,5,1.27,1.41,1.14,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,6A,1.17,1.33,1.02,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After 2-Dose Infant Series,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,7F,2.06,2.26,1.88,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,4,0.53,0.59,0.48,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,6B,0.61,0.69,0.54,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,9V,0.48,0.52,0.43,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,14,2.03,2.3,1.79,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,18C,0.35,0.39,0.32,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,19F,0.94,1.06,0.83,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,23F,0.26,0.29,0.23,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,1,0.68,0.75,0.61,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,3,0.25,0.27,0.22,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,5,0.88,0.97,0.8,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,6A,0.81,0.92,0.72,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC Before Toddler Dose,OG001,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).,One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),IgG,2,265,7F,0.76,0.82,0.7,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,5,4.77,5.3,4.29,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,6B,10,11.38,8.79,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,9V,3.02,3.32,2.74,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,14,10.3,11.47,9.26,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,18C,2.83,3.14,2.55,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,19F,9.01,10.36,7.84,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,23F,3.43,3.88,3.02,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,246,4,5.76,6.47,5.12,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,5,7.08,7.83,6.41,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,6B,10.39,11.82,9.14,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,9V,4.1,4.51,3.72,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,14,11.99,13.35,10.77,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,18C,4.26,4.7,3.85,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,19F,8.06,9.21,7.06,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,23F,4.87,5.51,4.3,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion criteria:

Aged 3 months (75 to 105 days) at time of enrollment.
Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
Known or suspected immune deficiency or suppression.
History of culture-proven invasive disease caused by S pneumoniae or Hib.
Major known congenital malformation or serious chronic disorder.
Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
Participation in another investigational trial. Participation in purely observational studies was acceptable.
Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.",Accepts Healthy Volunteers,All,75 Days,105 Days,"[""Child""]",[],Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy",<time.Time Value>,<time.Time Value>,<time.Time Value>,7vPnC After Toddler Dose,OG001,Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).,One month after toddler dose (12 months of age),IgG,4,249,4,0.03,0.04,0.03,PCV7,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,4,1.29,1.46,1.14,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,6B,0.74,0.89,0.62,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,9V,1.15,1.28,1.03,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,14,2.74,3.16,2.38,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,18C,1.42,1.6,1.26,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,19F,1.55,1.7,1.42,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).",One month after the 3-Dose Infant Series (at 5 months of age),IgG,3,266,23F,0.92,1.06,0.8,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,1,126,158.97,99.87,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,3,345.33,402.8,296.06,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,5,244.18,297.92,200.14,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,6A,1346.83,1585.65,1143.98,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,7F,8126.24,9919.21,6657.36,PCV13,,Pfizer,0,,0
"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","Inclusion Criteria:

Healthy 2-month-old infants.
Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Randomized,Parallel Assignment,Quadruple,Prevention,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC/13vPnC After Toddler Dose,OG000,"Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.",One month after the toddler dose (at 13 months of age),OPA,4,241,19A,804.06,1049.71,615.9,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,4,6.76,7.59,6.02,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,6B,4.77,5.59,4.07,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,9V,3.39,3.78,3.03,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,14,14.69,16.26,13.26,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,18C,3.68,4.14,3.27,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,19F,5.71,6.65,4.9,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,23F,2.57,3,2.21,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,1,5.11,5.82,4.48,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,3,2.87,3.24,2.55,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,5,3.85,4.33,3.42,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,6A,3.77,4.25,3.35,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,7F,5.78,6.45,5.19,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Infant Series,OG000,"Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) at approximately 2, 4, 6 months (infant series).",one mone month after 3-dose infant series (at 7 months of age),IgG,3,176,19A,6.97,7.77,6.25,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,4,9.7,11.17,8.43,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,6B,14.61,17.05,12.52,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,9V,4.49,5.06,4,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,14,16.33,18.41,14.49,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,18C,6.09,6.95,5.34,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,19F,12.2,14.35,10.37,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,23F,6.55,7.75,5.53,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,1,9.85,11.27,8.62,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,3,2.06,2.32,1.83,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,5,7.31,8.2,6.52,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,6A,11.03,12.55,9.69,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,7F,8.31,9.35,7.39,PCV13,,Pfizer,0,,0
"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","Inclusion Criteria:

Healthy 2 to 6 month-old infant
Available for entire study period

Exclusion Criteria:

Previous vaccination with licensed or investigational pneumococcal vaccine.
Previous anaphylactic reaction to any vaccine or vaccine-related component.
Contraindication to vaccination with a pneumococcal conjugate vaccine.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
Known or suspected immune deficiency or suppression.",Accepts Healthy Volunteers,All,2 Months,6 Months,"[""Child""]",[],Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC After Toddler Dose,OG000,Participants received one single 0.5mL dose of 13vPnC at 12-15 months of age (toddler dose),one month after the toddler dose (at 12-15 months of age),IgG,4,178,19A,15.97,18.13,14.07,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,4,3.48,3.88,3.12,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,6B,5.02,5.9,4.27,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,9V,2.34,2.6,2.11,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,14,9.35,10.82,8.07,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,18C,2.5,2.81,2.23,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,19F,3.75,4.29,3.28,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,23F,1.83,2.17,1.55,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,1,4.23,4.79,3.73,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,3,1.17,1.33,1.03,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,5,3.11,3.52,2.75,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,6A,4.08,4.68,3.56,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,7F,3.71,4.12,3.34,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 3 of infant series (6 months of age),IgG,3,171,19A,4.19,4.74,3.71,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,4,5.1,5.89,4.41,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,6B,15.41,18.38,12.92,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,9V,3.76,4.29,3.29,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,14,10.62,12.32,9.16,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,18C,3.93,4.48,3.45,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,19F,11.33,13.26,9.68,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,23F,5.7,6.77,4.81,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,1,5.86,6.75,5.08,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,3,1.62,1.84,1.42,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,5,4.75,5.4,4.18,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,6A,11.64,13.64,9.93,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,7F,5.81,6.51,5.18,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Toddler Dose (12 months of age),IgG,4,137,19A,8.95,10.23,7.84,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,4,3.54,3.97,3.16,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,6B,0.84,0.98,0.71,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,9V,1.82,2.08,1.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,14,5.54,6.5,4.72,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,18C,1.8,2.07,1.56,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,19F,4.14,4.78,3.59,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,23F,0.84,0.99,0.71,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,1,3.41,3.89,3,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,3,1.11,1.23,1.01,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,5,1.89,2.13,1.67,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,6A,1.86,2.16,1.6,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,7F,2.98,3.29,2.7,PCV13,,Pfizer,0,,0
"North America,North America,North America,North America,North America,North America,North America,North America,North America","Inclusion Criteria:

Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
Able to complete three blood draws during study
At least 3.5 kg at enrollment

Exclusion Criteria:

Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines
Immune deficiency, bleeding disorder or significant chronic medical condition",Accepts Healthy Volunteers,All,42 Days,98 Days,"[""Child""]",[],Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico,Wyeth is now a wholly owned subsidiary of Pfizer,Wyeth is now a wholly owned subsidiary of Pfizer,Interventional,Phase 3,Non-Randomized,Single Group Assignment,None (Open Label),Prevention,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico",<time.Time Value>,<time.Time Value>,<time.Time Value>,13vPnC,OG000,"13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose)",Dose 2 of infant series (4 months of age),IgG,2,195,19A,3.52,4.03,3.07,PCV13,,Pfizer,0,,0
